0,1,2,3,4
Table 3.10: Suggested strategy for antithrombotic therapy in stone removal [333-335],,,,
Medication/Agent,"Bleeding risk of 
planned procedure",Risk of thromboembolism,,
,,Low risk,Intermediate risk,High risk
"Warfarin 
Dabigatran 
Rivaroxaban 
Apixaban",Low-risk procedure,May be continued,Bridging therapy,Bridging therapy
,High-risk procedure,"May be temporarily 
discontinued at 
appropriate interval.
Bridging therapy 
is strongly 
recommended.",Bridging therapy,Bridging therapy
Aspirin,Low-risk procedure,Continue,Continue,"Elective surgery: 
postpone.
Non-deferrable 
surgery: continue."
,High-risk procedure,Discontinue,"Elective surgery: 
postpone.
Non-deferrable 
surgery: continue, if 
it is possible.","Elective surgery: 
postpone.
Non-deferrable 
surgery: continue."
"Thienopyridine 
agents (P2Y12 
receptor inhibitors)",Low-risk procedure,"Discontinue 
five days before 
intervention.
Resume within 
24-72 hours with a 
loading dose.",Continue,"Elective surgery: 
postpone.
Non-deferrable 
surgery: continue."
,High-risk procedure,"Discontinue 
five days before 
intervention and 
resume within 24-72 
hours with a loading 
dose.","Elective surgery:
postpone.
Non-deferrable
surgery: discontinue
five days before
procedure and
resume within 24-72 
hours with a loading 
dose.
Bridging therapy
-glycoprotein IIb/IIIa 
inhibitors if aspirin is 
discontinued.","Elective surgery:
postpone.
Non-deferrable 
surgery: discontinue 
five days before 
procedure and 
resume within 24-72 
hours, with a loading 
dose.
Bridging therapy
-glycoprotein IIb/IIIa
inhibitors."
